Daniel Allen Gold, Director at Roivant Sciences Ltd. (ROIV), sold 1,225,784 shares at $26.67 ($32.7M) on 2026-02-11, disclosed to the SEC on 2026-02-13.
Open-market sale of $32.7M ROIV by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.67 | 425,000 | $11.3M | 34.7% |
| 2 | $26.72 | 150,000 | $4.0M | 12.3% |
| 3 | $26.76 | 275,000 | $7.4M | 22.5% |
| 4 | $26.49 | 150,784 | $4.0M | 12.2% |
| 5 | $26.50 | 225,000 | $6.0M | 18.3% |
| Total | $26.64 avg |
| 1,225,784 |
| $32.7M |
| 100% |
| Filing → |
| ROIV | SELL | 2025-12-18 | $71.8M | — | Filing → |
| ROIV | SELL | 2025-11-21 | $29.8M | — | Filing → |
| ROIV | SELL | 2024-09-26 | $92.7M | — | Filing → |